Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization

Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly’s Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage bio ...